BD Targets Hospital-Associated Infections With $230 Mil. Acquisition
This article was originally published in The Gray Sheet
Executive Summary
BD's acquisition of molecular diagnostic firm GeneOhm Sciences enters the medical technology company into the purportedly $500 mil.-plus healthcare-associated infections market